Global News

Mast to develop Vepoloxamer (MST-188) in chronic heart failure

Friday, March 27, 2015 01:15 PM

Mast Therapeutics, a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, plans to develop vepoloxamer (MST-188) for the treatment of patients with chronic heart failure. Encouraged by recently reported nonclinical results and input from experts in the field, the company expects to begin dosing in a phase II study of vepoloxamer in patients with chronic heart failure in the third quarter of this year.

More... »

Quest Diagnostics

Ablynx, Merck extend ion channel research collaboration

Friday, March 27, 2015 11:21 AM

Ablynx, a biopharmaceutical company headquartered in Belgium, has extended its initial two-year research collaboration with Merck to develop and commercialize Nanobody candidates directed toward an undisclosed voltage gated ion channel.

More... »


PPD first to migrate data to the Oracle Health Sciences Cloud

Thursday, March 26, 2015 02:58 PM

PPD is the first company to migrate trials from an on-site installation of Oracle Health Sciences’ Siebel Clinical Trial Management System to Siebel Clinical Trial Management System Cloud Service—creating a highly available, centralized trial database that lowers costs, simplifies management, improves the accuracy of multi-CRO clinical trial data and accelerates studies.

More... »

Parexel to acquire Quantum Solutions India

Thursday, March 26, 2015 02:56 PM

Parexel International, a Boston-based global CRO, has signed a definitive agreement to acquire all of the business assets of privately-owned Quantum Solutions India (QSI), a provider of specialized pharmacovigilance services.

More... »

CluePoints, ACRES partner to improve data quality in clinical research

Thursday, March 26, 2015 02:55 PM

CluePoints, a Belgium-based provider of Centralized Statistical Monitoring (CSM) solutions for clinical trials, has partnered with the Alliance for Clinical Research Excellence and Safety (ACRES), a Massachusetts-based nonprofit dedicated to building a stakeholder-driven integrated global system for clinical research.

More... »

GSK's 2015 Discovery Fast Track Challenge seeks early drug discovery partnerships

Thursday, March 26, 2015 02:54 PM

GlaxoSmithKline is encouraging academic scientists in Europe, Canada and the U.S. to submit their novel early drug discovery research proposals into its third annual Discovery Fast Track Challenge—a program designed to accelerate the translation of early-stage research into game-changing new medicines. The challenge provides a new template for drug discovery as it seeks to rapidly uncover the best opportunities for discovery research.

More... »

Recipharm, Adroit Science collaborate to expand service offering

Thursday, March 26, 2015 02:51 PM

Two Swedish companies, Recipharm, a contract development and manufacturing organization (CDMO), and Adroit Science, a provider of laboratory and consultancy services, have formed a new strategic collaboration.

More... »

Shire, Cincinnati Children's establish rare disease research collaboration

Thursday, March 26, 2015 02:37 PM

Shire and Cincinnati Children's Hospital Medical Center have announced a three-year, broad research collaboration for rare diseases. The goal of the collaboration is to discover and develop novel therapies to treat rare diseases with high unmet medical need combining Shire's development and commercialization capabilities with Cincinnati Children's research experience.

More... »

Report: Antibiotics pipeline boasts 741 products, first-in-class development remains low

Wednesday, March 25, 2015 03:17 PM

While antibiotics boast a vast pipeline, with 741 products currently in development, the majority is dominated by generics, as weak financial incentives and high failure rates have discouraged innovation, said business intelligence provider GBI Research, a New York-based provider of business intelligence reports.

More... »

Forma Therapeutics, Cancer Research Technology form two virtual companies

Wednesday, March 25, 2015 03:11 PM

Forma Therapeutics, headquartered in Watertown, Mass., and Cancer Research Technology (CRT) have formed two new virtual Asset Discovery and Development Companies (ADDCos) with novel chemical matter targeting undisclosed deubiquitinating enzymes (DUBs). ADDCos are virtual companies seeking to achieve rapid innovation in a compelling scientific area through the collaboration of academic thought leaders, drug discovery scientists and a development network.

More... »

`

CWWeekly

March 30

Icon, Carnegie Mellon partner to research ways to improve study patients' understanding of Informed Consent

Veeva launches OpenKey, partner program to unlock difficult access to, restrictions on customer reference data

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

April

PSI, INC Research, Chiltern best with sites
Strategic outsourcing prioritizing, improving site relationships

Regulatory compliance an increasing burden on sites
Increased staff time, materials, storage eroding site operating profit

Already a subscriber?
Log in to your digital subscription.

Purchase the March issue.

Subscribe to
The CenterWatch Monthly.

The CenterWatch Monthly

March

Novo Nordisk, Takeda, Servier, Celgene among top sponsors
New gains seen from patient- and site-centric initiatives

Patient reported outcomes take center stage
FDA combining PROs, clinical outcomes in its approval decisions

Already a subscriber?
Log in to your digital subscription.

Purchase the February issue.

Subscribe to
The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs